科興製藥(688136.SH):公司海外銷售的產品品類及覆蓋的國家將得到較大豐富和提升
格隆匯6月26日丨有投資者向科興製藥(688136.SH)提問:2022年海外銷售收入拆分,分國家及產品的情況如何?
科興製藥回覆:2022年,公司實現外銷收入1.61億人民幣,主要產品為人促紅素(依普定)、人粒細胞刺激因子(白特喜),分別實現收入13,131萬元、2,879萬元。
公司實現外銷的國家中,收入佔比最大的國家為巴西,2022年實現6,331萬元 ,其他收入超過1,000萬元的國家包括墨西哥、菲律賓、埃及等國。
隨着公司已引進的7款產品陸續完成海外註冊開始實現銷售,公司海外銷售的產品品類及覆蓋的國家將得到較大豐富和提升,並將在抗腫瘤、自身免疫,代謝性疾病等治療領域形成產品矩陣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.